Meeting
2019 ASCO Annual Meeting
Proteomic profile of high-risk luminal A early breast cancers.
Authors
Nawale Hajjaji
Centre Oscar Lambret, Lille, France
Nawale Hajjaji , Soulaimane Aboulouard , Yves-Marie Robin , Delphine Bertin , Isabelle Fournier , Jacques Bonneterre , Michel Salzet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3077)
DOI
10.1200/JCO.2019.37.15_suppl.3077
Abstract #
3077
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).
First Author: Joannie M. Ivory
Poster
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
First Author: Alice P. Chung
Poster
2021 ASCO Annual Meeting
Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.
First Author: Joyce O'Shaughnessy
Poster
2021 ASCO Annual Meeting
Trends in breast cancer mortality according to molecular subtypes: A population-based study.
First Author: Yunan Han